Stockscreener 앱 받기
20.24
2.17%
-0.45
시간 외 거래:
20.38
0.14
+0.69%
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Trend Tracker for (SMMT) - Stock Traders Daily
Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics - Benzinga
Summit CEO Bob Duggan Sued Over 'Outlandish' Self-Dealing Loan - Bloomberg Tax
Is Summit Therapeutics a Millionaire Maker? - Nasdaq
Cantor Fitzgerald Initiates Coverage of Summit Therapeutics (BMV:SMMT) with Overweight Recommendation - Nasdaq
Summit rises as Cantor becomes latest to launch with a bullish view - MSN
Cantor Fitzgerald Initiates Coverage of Summit Therapeutics (SMMT) with Overweight Recommendation - Nasdaq
Summit Therapeutics grants stock options to new employees By Investing.com - Investing.com Canada
Summit Therapeutics grants stock options to new employees - Investing.com India
Summit Therapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4) -March 21, 2025 at 04:20 pm EDT - Marketscreener.com
Summit Therapeutics Awards 147,500 Shares in Strategic Employee Stock Options - StockTitan
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance UK
Summit stock rises after Cantor's bullish view (SMMT:NASDAQ) - Seeking Alpha
Cantor Fitzgerald Initiates Summit Therapeutics at Overweight -March 21, 2025 at 07:27 am EDT - Marketscreener.com
This Unstoppable Biotech Stock Just Became an Even Better Buy - The Globe and Mail
Summit Therapeutics Names Robert LaCaze as Chief Commercial Officer -March 18, 2025 at 03:30 am EDT - Marketscreener.com
Summit Therapeutics : Completion of $50 million Fundraising and Directorate Change - Marketscreener.com
Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer - Business Wire
Evercore ISI Group Initiates Coverage of Summit Therapeutics (BMV:SMMT) with Outperform Recommendation - Nasdaq
Summit gains as Evercore highlights potential to rival Merck’s Keytruda - MSN
Applovin, Super Micro Computer And Intel Among Top 10 Large-Cap Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio? - Benzinga
Summit Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:SMMT - Benzinga
(SMMT) On The My Stocks Page - Stock Traders Daily
Summit Therapeutics issues stock options to new employees By Investing.com - Investing.com Australia
Summit Therapeutics issues stock options to new employees - Investing.com India
Summit Therapeutics Stock Climbs 4%, Share Price Hits $19.96 - TradingPedia
Why Summit Therapeutics Stock Was Winning This Week - MSN
SMMT Gains on Bullish Analyst Coverage - GuruFocus.com
Summit Therapeutics (NASDAQ:SMMT) Coverage Initiated at Evercore ISI - Defense World
Is Summit Therapeutics Inc. (SMMT) the Best Multibagger Stock to Buy in 2025? - Insider Monkey
This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year - Nasdaq
Evercore ISI Initiates Summit Therapeutics at Outperform With $30 Price Target -March 12, 2025 at 12:08 pm EDT - Marketscreener.com
Summit Therapeutics Shares Surge on Promising Trial Results - TipRanks
Evercore ISI Group Initiates Coverage of Summit Therapeutics (SMMT) with Outperform Recommendation - Nasdaq
Summit Therapeutics initiated with an Outperform at Evercore ISI - TipRanks
12 Best Multibagger Stocks to Buy in 2025 - Insider Monkey
Stifel maintains Buy on Summit Therapeutics, $40 target By Investing.com - Investing.com Canada
Summit Therapeutics Inc. (SMMT): Why Are Analysts Bullish On This Hot Growth Stock Right Now? - Insider Monkey
New York State Common Retirement Fund Grows Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Principal Financial Group Inc. Acquires 147,003 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Summit Therapeutics (NASDAQ:SMMT) Stock Rating Upgraded by StockNews.com - Defense World
(SMMT) Investment Analysis and Advice - Stock Traders Daily
Rhumbline Advisers Has $2.23 Million Stock Position in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Summit Therapeutics (NASDAQ:SMMT) Earns Buy Rating from Analysts at The Goldman Sachs Group - MarketBeat
Equities Analysts Offer Predictions for SMMT Q1 Earnings - MarketBeat
Summit Therapeutics' (SMMT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Goldman Sachs Initiates Coverage of Summit Therapeutics (SMMT) with Buy Recommendation - MSN
StockNews.com Downgrades Summit Therapeutics (NASDAQ:SMMT) to Sell - MarketBeat
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
0.03%
1.06%
자본화:
|
볼륨(24시간):